Adicet Bio, Inc. — Director's Dealing 2021

Oct 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2021-10-12

Reporting Person: Aftab Blake (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-12	Common Stock	A	80000	$0.00	Acquired	80000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-12	Stock Option (right to Buy)	$7.38	A	60000	Acquired	2031-10-11	Common Stock (60000)	Direct

Footnotes

F1: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 12, 2022 and the second tranche vesting on October 12, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

F2: 25% of the shares subject to the stock option shall vest on October 12, 2022, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter, subject to continued service with the Company.